BC
NBRV

Boxer Capital’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History

Boxer Capital’s Portfolio NBRV Stock Details NBRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-347
Closed -$710K – 34
2017
Q3 		$710K Sell
347
-360
-51% -$844K 0.16% 28
2017
Q2 		$1.85M Hold
707
– – 0.44% 24
2017
Q1 		$2.12M Hold
707
– – 0.46% 23
2016
Q4 		$1.05M Hold
707
– – 0.41% 21
2016
Q3 		$1.25M Hold
707
– – 0.56% 23
2016
Q2 		$1.32M Hold
707
– – 1.17% 21
2016
Q1 		$1.58M Hold
707
– – 1.55% 15
2015
Q4 		$1.69M Buy
+707
New +$1.72M 1.46% 12

Other funds holding NBRV

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Boxer Capital's NBRV Position: Q4 2017 in Review

Boxer Capital sold out of Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q4 2017, closing a stake of 347 shares — an estimated $710K sold.

Boxer Capital first reported a position in NBRV in Q4 2015 and held it in 8 quarters. The position peaked at $2.12M in Q1 2017. 45 funds tracked by Wall St. Rank hold NBRV as of Q4 2017.

  • Boxer Capital reported no remaining Nabriva Therapeutics plc Ordinary Shares Ireland position as of Q4 2017 after selling out during the quarter.
  • Boxer Capital sold 347 Nabriva Therapeutics plc Ordinary Shares Ireland shares in Q4 2017, an estimated $710K.
  • Boxer Capital first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q4 2015 and held it in 8 quarters.
  • Boxer Capital's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $2.12M in Q1 2017.
  • 45 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q4 2017.

Based on Boxer Capital's 13F filing for Q4 2017, filed 14 Feb 2018.